Wikipedia
Linking: http://en.wikipedia.org/wiki/Pantoprazole
Pantoprazole’s labeled indication is for the short-term treatment
(no more than 16 weeks) of erosive esophagitis associated with gastroesophageal
reflux disease (GERD). It may also show benefit for the maintenance treatment of
erosive esophagitis, the treatment of duodenal and gastric ulcers, the
prevention of gastro-duodenal damage in patients taking NSAIDs, and as
adjunctive therapy with antibiotics for the eradication of Helicobacter
pylori. Intravenous pantoprazole is indicated for the short-term
treatment (7-10 days) of GERD, as an alternative for those patients who are
unable to take the oral formulation. Other potential uses for
intravenous pantoprazole include prevention of aspiration pneumonia in patients
undergoing surgery, prevention of stress ulcers in intensive care patients,
treatment of pyloric channel ulcers, and treatment of Zollinger-Ellison
syndrome. (http://www.hsc.wvu.edu/)
Metabolism: Pantoprazole is extensively metabolized
in the liver through the cytochrome P450 (CYP) system.
Pantoprazole metabolism is independent of the route
of administration (intravenous or oral). The main metabolic
pathway is demethylation, by CYP2C19, with subsequent
sulfation; other metabolic pathways include oxidation
by CYP3A4. There is no evidence that any of the pantoprazole
metabolites have significant pharmacologic activity.
CYP2C19 displays a known genetic polymorphism due to
its deficiency in some sub-populations (e.g. 3% of Caucasians
and African-Americans and 17-23% of Asians). Although
these sub-populations of slow pantoprazole metabolizers
have elimination half-life values of 3.5 to 10.0 hours,
they still have minimal accumulation (≤ 23%) with once
daily dosing. (http://www.accessdata.fda.gov/)
An
analogue to omeprazole,
used in the treatment of erosive
esophagitis
associated with gastroesophageal
reflux disease, administered orally or intravenously, and of pathological hypersecretion
associated with Zollinger-Ellison
syndrome or other neoplastic conditions, administered intravenously.
|